Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERIDONE vs ARIPIPRAZOLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.
Schizophrenia,Bipolar I disorder (acute manic or mixed episodes),Irritability associated with autistic disorder,Adjunctive therapy in major depressive disorder,Tourette syndrome (off-label),Obsessive-compulsive disorder (off-label)
Schizophrenia,Acute manic and mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Adjunctive treatment of major depressive disorder,Irritability associated with autistic disorder,Tourette's disorder
Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.
Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.
Risperidone: 3 hours (CYP2D6 extensive metabolizers), 20 hours (poor metabolizers); active metabolite 9-hydroxyrisperidone: 21-30 hours; steady-state reached in 5-6 days
Aripiprazole has a terminal elimination half-life of approximately 75 hours in extensive CYP2D6 metabolizers and about 146 hours in poor metabolizers. The active metabolite, dehydro-aripiprazole, has a half-life of about 94 hours. This long half-life allows for once-daily dosing and gradual achievement of steady state (14 days in extensive metabolizers).
Extensively metabolized in the liver via CYP2D6 and CYP3A4 to 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. The parent drug and metabolite are equally active.
Primarily hepatic via CYP2D6 and CYP3A4.
Renal (70% as metabolites, 14% as parent drug) and fecal (14%)
Aripiprazole is extensively metabolized primarily by the liver via CYP2D6 and CYP3A4. Approximately 25% of the dose is excreted unchanged in urine, and about 55% in feces. The major metabolite, dehydro-aripiprazole, accounts for about 40% of the AUC and is also excreted in urine and feces.
Risperidone: 90% bound to albumin and alpha-1-acid glycoprotein; 9-hydroxyrisperidone: 77% bound
Aripiprazole is >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High protein binding means that changes in protein levels (e.g., hypoalbuminemia) can affect free drug concentration.
Risperidone: 1-2 L/kg; 9-hydroxyrisperidone: 0.5-1 L/kg; extensive tissue distribution
The volume of distribution (Vd) for aripiprazole is approximately 4.9 L/kg, indicating extensive tissue distribution (well beyond total body water). This large Vd suggests significant partitioning into tissues, which contributes to the long half-life.
Oral: 70% (tablet), 70% (oral solution); intramuscular: 100% for immediate-release, 28% for long-acting injection relative to oral
Oral: The absolute bioavailability of aripiprazole tablets is approximately 87%. Bioavailability is not significantly affected by food. Intramuscular immediate-release: Bioavailability is 100% for the IM formulation relative to oral. The long-acting injectable (aripiprazole lauroxil) has a bioavailability of about 100% compared to oral aripiprazole after reaching steady state.
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: initiate at 0.5 mg orally twice daily for at least 1 week, then increase by 0.5 mg twice daily as tolerated; maximum 3 mg/day.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). For severe renal impairment (Cr Cl <15 m L/min), use with caution; limited data suggests no adjustment needed, but monitor tolerability.
Child-Pugh Class A or B: initiate at 0.5 mg orally twice daily, increase cautiously. Class C: avoid or use with extreme caution; no specific established dose.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): start at 10 mg/day; titrate cautiously. Child-Pugh Class C (severe): avoid use; if unavoidable, start at 5 mg/day and titrate slowly.
Adolescents (13-17 yr) with schizophrenia: initial 0.5 mg orally once daily, titrate to 3 mg/day as tolerated. Children (10-17 yr) with bipolar mania: initial 0.5 mg once daily, titrate to 1-2.5 mg/day. Weight-based not standard; use fixed dosing.
Schizophrenia (≥13 years): 10-15 mg/day initially; target 15 mg/day; max 30 mg/day. Irritability associated with autistic disorder (6-17 years): 5-10 mg/day; start at 2.5 mg/day for ≥30 kg and 5 mg/day for <30 kg; titrate gradually. Tourette's disorder (6-18 years): 5-10 mg/day; start at 2.5 mg/day for <50 kg and 5 mg/day for ≥50 kg; max 10 mg/day.
Initiate at 0.5 mg orally once daily; increase by 0.5 mg/day increments; target dose 1-2 mg/day; monitor for orthostasis and extrapyramidal symptoms.
Initiate at 10 mg/day; titrate slowly due to increased sensitivity and risk of hypotension, sedation, and extrapyramidal symptoms. Maximum 15 mg/day in elderly patients with psychosis. Consider lower initial doses (2-5 mg/day) in frail patients.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
Increased risk of death in elderly patients with dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (stroke, TIA) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Hyperprolactinemia,Orthostatic hypotension,Seizures,Leukopenia/neutropenia/agranulocytosis,QT interval prolongation,Priapism,Dysphagia,Body temperature dysregulation,Potential for cognitive and motor impairment
Increased risk of cerebrovascular events in elderly with dementia, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, cognitive and motor impairment, and body temperature dysregulation.
Hypersensitivity to risperidone or any component of the formulation
Hypersensitivity to aripiprazole or any components of the formulation.
Avoid grapefruit and grapefruit juice; may increase risperidone plasma concentrations. Alcohol can potentiate CNS depression and increase risk of side effects. No specific food restrictions; take with or without food. High-fat meals may slightly increase absorption.
No significant food interactions. Absorption unaffected by food. Avoid grapefruit juice as it may increase aripiprazole levels via CYP3A4 inhibition.
Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposure may cause neonatal extrapyramidal symptoms (e.g., agitation, hypertonia, tremors) and withdrawal symptoms (e.g., respiratory distress, feeding difficulties).
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: Possible risk of extrapyramidal symptoms or withdrawal in neonates; risk of gestational diabetes and weight gain. Overall, not a major human teratogen but risk-benefit assessment required.
Risperidone is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5 for the parent drug and 0.3 for the active moiety (risperidone + 9-hydroxyrisperidone). Relative infant dose (RID) is about 2-4% of the maternal weight-adjusted dose. Monitor the infant for sedation, poor feeding, and extrapyramidal effects. The benefit of breastfeeding should be weighed against potential risks.
Aripiprazole is excreted into breast milk; estimated relative infant dose is 1-8% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. potential risks.
Increased clearance of risperidone in pregnancy may require dose adjustments. Some studies suggest a dose increase of 20-30% during the second and third trimesters to maintain therapeutic levels. TDM is recommended to guide dosing, with target trough concentrations similar to non-pregnant patients (10-20 ng/m L for the active moiety). Postpartum dose should be reduced to pre-pregnancy levels.
Increased clearance and volume of distribution in pregnancy may necessitate dose increases, especially in the third trimester. Therapeutic drug monitoring if available; adjust based on clinical response and tolerability. Postpartum, reduce to prepregnancy dose to avoid toxicity.
Monitor for orthostatic hypotension, especially during dose titration. Risperidone can cause QTc prolongation; obtain baseline ECG in at-risk patients. Extrapyramidal symptoms (EPS) are dose-dependent; use lowest effective dose. In elderly dementia patients, increased risk of cerebrovascular events; not approved for this indication. Prolactin elevation is common; monitor for gynecomastia, galactorrhea, and sexual dysfunction. Taper slowly to avoid withdrawal dyskinesia.
Aripiprazole is a partial dopamine agonist, distinguishing it from typical antipsychotics. Monitor for akathisia, especially during titration. QT prolongation risk is lower than with other antipsychotics, but ECG is recommended in patients with cardiac risk. Tardive dyskinesia risk exists but may be lower than with typical agents. Avoid abrupt discontinuation to prevent withdrawal dyskinesias. Metabolized by CYP2D6 and CYP3A4; dose adjustments needed with CYP2D6 inhibitors or poor metabolizers. May cause orthostatic hypotension; titrate slowly. Weight gain and metabolic effects are less pronounced than with olanzapine or clozapine, but still monitor weight, lipids, and glucose.
Take risperidone exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol and grapefruit juice as they may affect drug levels and increase side effects.,Rise slowly from sitting or lying down to prevent dizziness from low blood pressure.,Report any involuntary muscle movements, restlessness, or stiffness to your healthcare provider.,Notify your doctor if you experience breast swelling, discharge, or sexual problems.,Do not drive or operate heavy machinery until you know how risperidone affects you.
Take once daily without regard to meals. Swallow tablets whole, do not crush or chew.,May cause dizziness or drowsiness, especially when starting; avoid driving until you know how it affects you.,Do not stop taking suddenly without consulting your doctor, as this may cause withdrawal symptoms.,Report any restlessness, muscle stiffness, fever, or unusual movements to your doctor immediately.,Limit alcohol intake as it can increase side effects like drowsiness.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Regular blood tests may be needed to check for effects on blood sugar and cholesterol.
"Carvedilol, a nonselective beta-blocker with alpha1-blocking activity, may enhance the hypotensive effects of risperidone, an atypical antipsychotic with alpha1-adrenergic antagonism. This additive pharmacodynamic interaction can lead to exaggerated blood pressure reduction, orthostatic hypotension, dizziness, and increased risk of syncope, particularly during initial dosing or dose titration. Patients with cardiovascular comorbidity or volume depletion are at heightened risk for adverse outcomes such as falls or cardiac ischemia."
"Cilazapril, an angiotensin-converting enzyme inhibitor (ACEI), reduces angiotensin II production and aldosterone secretion, leading to vasodilation and decreased blood pressure. Risperidone, an atypical antipsychotic, can cause orthostatic hypotension through alpha-1 adrenergic receptor blockade. Concurrent use may result in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope, particularly at treatment initiation or dose adjustments."
"Coadministration of risperidone and pizotifen may lead to additive anticholinergic and sedative effects due to their overlapping pharmacological profiles. Risperidone, an atypical antipsychotic with histamine H1 receptor antagonist properties, combined with pizotifen, a serotonin antagonist with strong anticholinergic and antihistaminergic activity, can result in excessive sedation, cognitive impairment, and peripheral anticholinergic effects such as dry mouth, constipation, and urinary retention. Clinically, this interaction increases the risk of falls, confusion, and reduced functional status, especially in elderly patients or those with pre-existing central nervous system depression."
"Aripiprazole, a partial dopamine D2 and serotonin 5-HT1A agonist, may have its adverse effects potentiated by methsuximide, a succinimide anticonvulsant that inhibits CYP3A4. This can lead to increased aripiprazole plasma concentrations, raising the risk of extrapyramidal symptoms, sedation, and QT prolongation. Clinical outcomes include heightened neurotoxicity and potential for arrhythmias."
"Concurrent use of aripiprazole and clonazepam increases the risk of central nervous system (CNS) depression, including excessive sedation, dizziness, ataxia, and impaired cognitive or motor function. This additive pharmacodynamic interaction results from the combined depressant effects on the CNS mediated by GABAergic potentiation from clonazepam and dopaminergic/serotonergic modulation from aripiprazole. Patients may experience heightened somnolence, psychomotor slowing, and an increased risk of falls, particularly during initiation or dose escalation."
"Aripiprazole, an atypical antipsychotic with partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors, can induce orthostatic hypotension, particularly during initial titration. This hypotensive effect may be additive when combined with moexipril, an ACE inhibitor that lowers blood pressure by inhibiting angiotensin II production. Concomitant use increases the risk of symptomatic hypotension, including dizziness, syncope, and falls, especially in elderly or volume-depleted patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERIDONE vs ARIPIPRAZOLE, answered by our medical review team.
RISPERIDONE is a Atypical Antipsychotic that works by Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.. ARIPIPRAZOLE is a Atypical Antipsychotic that works by Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERIDONE and ARIPIPRAZOLE depend on the specific clinical indication. These are both Atypical Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERIDONE is: Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.. The standard adult dose of ARIPIPRAZOLE is: Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining RISPERIDONE and ARIPIPRAZOLE. The risk or severity of adverse effects can be increased when Risperidone is combined with Aripiprazole. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. RISPERIDONE is classified as Category A/B. Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposu. ARIPIPRAZOLE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: P. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.